INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

16 March 2026

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

12 March 2026

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

11 March 2026

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

06 March 2026

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

06 March 2026

UltraPlex-TMT: Expanding Isobaric Hyperplexing via Orthogonal Protease Cleavage.

06 March 2026

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

04 March 2026

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

03 March 2026

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

03 March 2026

ESMO basic requirements for AI-based biomarkers in oncology (EBAI).

01 March 2026

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

24 February 2026

The two souls of pathology-ready for biomarker complexity.

23 February 2026